Ophthalmology assessments are pivotal in clinical trials, safeguarding participant health and ensuring accurate study outcomes. These evaluations identify potential side effects and verify treatment efficacy, making them indispensable across various therapeutic areas, from general medicine and rare diseases to oncology and neurology.
20/20 Onsite’s VP of Life Sciences Jessica McKenzie Mays agrees: "You can tell a lot about what's happening in a body through the eyes. You can diagnose a whole host of issues through a simple, noninvasive eye exam."
Integrating ophthalmology assessments into clinical trials presents several challenges. Clinical sites often face hurdles related to the following:
"We are creating a lot of ophthalmology health deserts across the U.S.," Mays noted, emphasizing the need to address accessibility and resource distribution. Overcoming these challenges requires effective strategies to streamline ophthalmology assessments and mitigate potential issues.
To overcome the barriers associated with ophthalmology assessments, implement robust solutions such as:
Addressing these areas can significantly improve the integration and execution of evaluations in clinical trials.
20/20 Onsite’s newly released guide, "Ophthalmology Assessments Made Simple: A Guide for Clinical Trials," is a valuable resource that provides insights into overcoming these challenges. This quick-start guide is designed to assist research sites, whether small or large, in navigating complexities and driving their clinical trials to success. It offers a breakdown of common ophthalmology assessments, insights into the overlooked hurdles of integration, and more.
Discover how leveraging advanced diagnostic technologies and strategic solutions can impact the cost and efficiency of common ocular assessments. This preview from our guide offers a glimpse into the financial and logistical considerations behind essential eye evaluations for optimizing clinical trial success.